Indian stocks: Visit www.stage2stocks.com →

OnKure Therapeutics, Inc. Class A

Stage 4 · Declining · week 4

As of Oct 22, 2026, OnKure Therapeutics is in Stage 4, the downtrend phase, now in week 4 (since Sep 29, 2026). It closed at $2.58, 51.0% below its 52-week high and below its 200-day average, which is falling.

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. More about the company

$2.58
+12.17% today
$104M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is OKUR early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 15w
S4 14w
S4 32w
S2 15w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S3 6w → S2 9w → S3 2w → S4 15w → S1 13w → S4 14w → S1 4w → S2 6w → S3 1w → S4 32w → S1 3w → S4 3w → S1 13w → S2 5w → S3 9w → S2 15w → S3 4w → S2 3w → S3 5w → S4 3w current
Total tracked: 165 weeks across 20 stage runs.

OKUR among Biotechnology227th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…227OKURStage 4 · wk 444−12.2%
vs 52W High
-51.0%
$2.10 lo$5.27 hi
51.0% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 4
1w13w26w
Week 4, early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-28.9%
200 DMA: $3.63 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.87x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-12.2%
3M
-37.4%
6M
-47.3%
YTD
-12.8%
1Y
-14.0%
Scan Membership
Breakout Watch
Latest: 2024-10-30
4 appearances in last 60 days. First seen: 2022-11-01.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 4 · Vol 0.87x
2026-10-21S4
Wk 4 · Vol 0.79x
2026-10-20S4
Wk 4 · Vol 0.85x
2026-10-19S4
Wk 3 · Vol 1.87x
2026-10-16S4
Wk 3 · Vol 1.47x
2026-10-15S4
Wk 3 · Vol 1.34x
2026-10-14S4
Wk 3 · Vol 1.49x
2026-10-13S4
Wk 3 · Vol 0.91x
2026-10-12S4
Wk 2 · Vol 0.57x
2026-10-09S4
Wk 2 · Vol 2.48x
2026-10-08S4
Wk 2 · Vol 2.19x
2026-10-07S4
Wk 2 · Vol 1.11x
Moving averages & range
50 DMA
$3.08
200 DMA
$3.63
52W High
$5.27
52W Low
$2.10
5D Low
$2.10
Resistance levels (recent highs)
20d High
$2.90
60d High
$4.21
120d High
$4.60
250d High
$5.27
Next resistance
+12.4%
to 20d High
ROE
-46.9%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 0.6

OnKure Therapeutics: quick answers

What stage is OnKure Therapeutics in?

As of Oct 22, 2026, OnKure Therapeutics (OKUR) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 29, 2026 and is in week 4. What the four stages mean

Is OnKure Therapeutics in an uptrend?

No. OnKure Therapeutics is in a Stage 4 downtrend. It trades 28.9% below its 200-day average, which is falling.

How far is OnKure Therapeutics from its 52-week high?

OnKure Therapeutics closed at $2.58 on Oct 22, 2026, 51.0% below its 52-week high of $5.27. Its 52-week low is $2.10.

How has OnKure Therapeutics performed over the past year?

As of Oct 22, 2026, OnKure Therapeutics is down 14.0% over the past year and down 12.8% so far in 2026.

Which sector and industry is OnKure Therapeutics in?

OnKure Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.